A Review of Diabetic Foot Ulcer Infections and Lyophilized Wafer Formulation

Rupalben Kaushalkumar Jani1*, Goswami Kaushal Puri1 and Shrestha Ubana1

1Department of Pharmaceutics, Parul Institute of Pharmacy and Research, Parul University, Wagholia Road, Vadodara-391760, Gujarat, India.

Authors’ contributions

This work was carried out in collaboration among all authors. Author RKJ designed the study and wrote the protocol. Author GKP wrote the first draft of the manuscript. Author SU managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i25B31457
Editor(s):
(1) Dr. Rahul S. Khupse, University of Findlay, USA.
Reviewers:
(1) Sara Paola Hernández Martínez, Universidad Autónoma de Nuevo León, México.
(2) Honghua Hu, Macquarie University, Australia.
Complete Peer review History: http://www.sdiarticle4.com//review-history/67417

Received 02 February 2021
Accepted 07 April 2021
Published 22 April 2021

ABSTRACT

Diabetic foot difficulties are the most usually occurring problems globally, resulting in economic disasters for the patients, families, and society. In patients with diabetes, the risk of emerging foot ulcers is 25% high. It has also been in the record that one lower limb amputation occurs every 30 seconds in patients with diabetes worldwide. Novel methods of drug delivery and wound dressing have to develop to solve the lower limb amputation crisis. One such novel method is "Lyophilized wafer formulation." It is an upcoming medicated dressing material that can enhance wound healing and the potential to ingest vast quantities of exudates from Chronic wounds. That can have been formulating by lyophilizing hydrogel of absorbent polymers such as Calcium Alginate, Carrageenan, Thiolated Chitosan, and plasticizer to enhance flexibility withstand the day to day mechanical stress, covered with some adhesive and protective backing layer. Unless it passes evaluation tests such as Fourier-transform infrared spectroscopy (FTIR), Differential scanning calorimetry (DSC), Scanning electron microscopy (SEM), Exudate handling property, Folding endurance, In-vitro, In-vivo drug release profile, and Gamma-irradiation sterilizes wafer formulation, and it should not administrate directly. Lyophilized wafer formulation will be the most acceptable medicated dressing material in the future that will be useful to treat the normal wound. The wound formation because of...
diabetic foot ulcer (DFU) infections as there will be site-specific delivery of the drug, packed with an advantage to self-administer and easy termination of the drug that can achieve just by removing the wafer case of drug toxicity.

Keywords: Calcium alginate; wafer formulation; lyophilization method; exudate handling property; In-vitro; In-vivo drug release studies; diabetic foot ulcer; lyophilizer.

1. INTRODUCTION

1.1 Diabetic Foot Ulcers

Diabetic foot ulcers describe foot abrasions as (ulcers). It may affect the skin, soft tissue, and bone in the lower limbs, contributing to more contagious diabetic patients, leading to outcomes such as lower-limb amputations [1]. A foot ulcer can occur in anyone, and it looks like a cover of broken-down skin, usually on the lower leg or feet. A foot ulcer can affect both Type one(1) and Type two(2) diabetes [2]. Colonization by Staphylococcus aureus, Streptococcus group B, Enterococcus, Clostridium perfringens, Enterobacteriaceae and other pathogenic species in DFUs, S. aureus, including methicillin-resistant S. aureus (MRSA) is the most common bacteria found in DFU infections [3]. Another significant complication of DFUs is osteomyelitis, and each person with infected DFUs needs to avoid [1]. Typically, when blood glucose levels are elevated or fluctuated, the skin wounds may not heal or repair themselves properly due to insufficient oxygen supply and clotting factors towards the wound site [4]. The foot ulcer can start even in a mild injury, leading to a change in the wound’s pH, ranging from 6.0 to 8.0 [5]. Persons suffering from chronic leg ulcers release 5 grams of exudate per 10 cm²/24h as per records [3].

It takes more than 12-14 weeks for a wound to heal in a Diabetic Foot ulcer/chronic wound as healing is slow due to inadequate delivery of Nutrients, blood cells and, oxygen in the blood at the wound site. Some of the common sites are shown in Fig. 1 [4].

Acute and Chronic are two types of wounds. Healing of both wounds consists of four cycles, but healing time may differ according to wound type. Below, the healing period mention for the chronic injury [4,6].

i. Hemostasis: In this cycle, coagulation factors occur when fibrinogen forms a fibrin network to stop bleeding. This activity may take quite a few minutes to 3 days [6,7].

ii. Inflammation: This cycle occurs continuously along with Hemostasis, and it can take 24 hrs to 20 days for the process [7,8].

iii. Cell proliferation/granulation: This cycle also occurs always along with Hemostasis, in which the formation of granules occurs by ingrowth of capillaries and lymphatic vessels. This process can take nearly 7-40 days [7,9].

iv. Remodeling or Maturation: In this phase, complete regeneration of skin takes place at the site of the wound just left with a scar and this process takes about 40 days to 2 years [6,7].

1.2 Pathophysiology

DFUs have complex pathogenesis, such as Diabetic Neuropathy and Peripheral Arterial Disease (PAD), which are the key variables affecting their development, with trauma being a triggering factor. Above all, these variables together take part in various stages of ulcer growth, as before and after a pause in wound healing, its occurrence [1,10].

1.2.1 Diabetic neuropathy

- Hyperglycemic-induced oxidative stress (OS) on nerve cells contributes to neuropathy, affecting sensitive, motor and autonomous nerves.
- Confines the alteration to NADPH of Nicotinamide Adenine Dinucleotide (NAD) by obstructing glucose-6-phosphate dehydrogenase activity [2].
- Increased nicotinamide adenine dinucleotide phosphate (NADPH) from certain enzymes via the polyol metabolic pathway absorbs. Such as Aldose reductase and Sorbitol dehydrogenase. Which further decreases by pathway activation of the hexosamine.
- The sweat gland is damage by autonomic nerve damage, and the foot may progress in a state of reduced capacity to moisturize the skin, resulting in dermal cracks and skin membrane breakdown [11].
1.2.2 Role of immunology in the pathogenesis of DFU'S

- Distinct resistant features occur in persons who have Diabetes that involve an abridged healing response in DFUs. Cellular resistant response alterations with enhanced T-lymphocyte apoptosis are some of these responses. Boost of pro-inflammatory cytokines. The deficiency of chemotaxis, adherence, phagocytosis, and intracellular killing functions of polymorphonuclear cells. The prohibition of fibroblast proliferation. Impairment of the basal keratinocyte layer with condensed epidermal cell movement prevents wound healing [10,12,13].
- High sugar levels in the blood are also an effective mediator for bacteria's progress, such as *Staphylococcus aureus* (S. aureus) and β-hemolytic streptococci, primarily aerobic Gram-positive cocci [14].

1.2.3 Peripheral Arterial Disease (Pad)

- It is in the records that 78% of DFU patients still have PAD. In the peripheral arteries of the foot, hyperglycemia induces changes and begins at the cellular level. A crucial feature of microcirculation dysfunction in endothelial cell dysfunction is a decrease in vasodilators, especially in nitric oxide synthesis.
- With consequent persistent vasoconstriction, Plasma Thromboxane A2 levels turn out to be elevated. Plasma hypercoagulation, which leads to an elevated risk of ulceration and ischemia [10,11].

1.3 Classification of Diabetic Foot Ulcer and Severity

A foot ulcer due to diabetes is classified either as Neuropathic or Ischaemic. Roughly 45% to 60% of all population are purely neuropathic diabetic ulcerations, despite the fact up to 45% are due to neuropathic and ischemic constituents [2,9,10].

1.3.1 Neuropathic

Neuropathic diabetic foot ulceration occurs due to the Motor, Sensory, and Autonomic Nervous system's failure [2,12].

i. Motor: It is a type of condition in which ankle motion decreases due to which plantar burdens on the barefoot increase. This type of disorder occurs due to the failure of motor nerves near the foot.

ii. Sensory: This condition occurs due to the loss of protective sensation in the foot area due to the sensory nerve’s improper functioning.

iii. Autonomic: In this condition, the foot's skin becomes dry by forming cracks and fissures, making way to enter bacteria and fungi. These may occur due to the dysfunction of microvascular thermoregulators, arteriovenous blockage, and sympathetic failure.
1.3.2 Ischaemic

Ischaemic diabetic foot ulceration occurs due to the narrowing of blood vessels. It contributes to less oxygen and nutrients provide to the tissues, and in this condition, oral or intravenous administration of antibiotics is less effective lead to the amputation of the limb.

Doctors use Wagner Grade to describe the seriousness of a foot ulcer. By using numbers from 0 to 5, six ranking systems classify diabetic foot ulcers \[2,12,15,16\].

Grades 0 to 5 by Wagner are as follows and presented in (Fig. 2).

0. There is no diabetic foot ulcer, but a significant risk of spreading one is present.

1. Full skin thickness includes a surface ulcer that does not affect the underlying tissues yet.

2. A deep ulcer permeates past the surface, down to the muscle and ligaments. There are also no abscesses or bones involved.

3. A profound ulcer arises with the tenderness of the subcutaneous connective tissue or a cyst. It may involve thew (muscle), ligament(tendon), near joint bones, and bone infections.

4. The tissue (limited to the foot and forefoot) around the ulcer region has started to decay. Gangrene is called this disease.

5. To become extensive, Gangrene spread from the localized region of the ulcer. The whole foot involves.

1.4 Causes for Diabetic Foot Ulcer

There are many reasons, which cause Diabetic Foot Ulcer. Some of them are as given below \[1,2,10,11,17\].

- Poor blood circulation
- Wearing poor fitting shoes
- Walking barefoot
- Insufficiently well-controlled diabetics
- Cigarette Smoking, become overweight, not having exercise, and improper cleaning of foot
- Uneven growth of foot nail
- History of prior ulcer/amputation

1.5 Risk Factors due to Diabetic Foot Ulcer

In Diabetic Foot Ulcer, the major risk factors in patients are as below \[2,9,18,19\].

Results

- Amputation of Limb
- Improper wound healing
- Longer wound healing time

Reasons

- Improper glycemic control
- Trauma

2. DIABETIC FOOT ULCER MANAGEMENT REMEDIES

2.1 Debridement

It should perform every 7-14 days. In this process, dead skin or debridement is removed by
Table 1. Available marketed products for topical therapies for wound healing and antimicrobial property

| Antibiotics              | Marketed product | Company                        |
|-------------------------|------------------|--------------------------------|
| Neomycin                | Ointment         | Neopharm Co., Ltd.             |
| Silver Sulfadiazine     | Cream            | Pfizer Laboratories.          |
| Bacitracin              | Powder           | Auro Pharma Inc.               |
| Mafenide                | Powder           | Mylan Bertek Pharmaceuticals Inc. |
| Povidone-Iodine         | Liquid           | Baxter Laboratories.           |
| Chlorhexidine           | Solution         | Cardinal Health               |
| Benzethonium Chloride   | Liquid           | Rite Aid Corporation          |

cutting it with a scalpel and tweezers or using a strong water jet. It prevents microbial growth and promotes wound healing. Cleaning of the lesion after debridement removal is carried by (0.9% NaCl) isotonic saline solutions [1].

**2.2 Topical Therapies**

It can also control by giving topical Antibiotics and Antiseptics such as Bacitracin, Neomycin, Mupirocin, Polymyxin B, Silver Sulfadiazine, Mafenide, Povidone-Iodine, Chlorhexidine and Benzethonium Chloride which are existing in the form of Creams, Powders and Ointments [10] given in (Table 1).

**2.3 Dressings**

It could also control by different dressing materials such as Hydrocolloids, Hydrogels, Foam, Calcium Alginate Dressing, and Wafers [1,10]. Among the above wound dressings, wafer formulation is the furthermost effective dressing in the sense of moisture handling capacity, Exudate absorbing capacity, wound healing, and antibiotic delivery in a single sauce in 24 hrs [3,20].

**3. WAFER FORMULATION**

As per et al. Anthony David Auffret, the lyophilized composite of the polymer substrate and plasticizer is known as a wafer. Along with stable crystalline particles of a pharmaceutically active compound, mainly used as a wound-healing agent. Which can be placed on an open wound, whether it is an Acute or Chronic wound [21].

**3.1 Lyophilizer**

- Freeze-drying or Lyophilization, also known as Cryodesiccation, is a very widely used method to formulate pharmacological and biological products to prolong shelf life. For example, vaccines and injectables are freeze-dried for ease of storage and shipping and later reformed to their original liquid form before use.
- Here, the hydrogel is freeze-dried to produce a crystalline, porous material known as ‘Sponges’ or ‘Wafers.’ The method of extracting water from the substance by first freezing it into ice and then sublimating it in the water vapor beneath reduced pressure is Freeze-drying or Lyophilization [22].
- The principle of freeze-drying can describe using a water phase diagram in (Fig. 3). The Freeze-drying process does not damage the integrity of the material's crystalline structure because the water gets removes in the form of vapor. The freeze-drying process involves 3 (three) phases Freezing, Primary drying, and Secondary drying.
- The solution is freeze to well below the triple-point temperature for pure water so that the evaporation can take place via sublimation, thus avoiding the liquid phase. By using a vacuum pump, the pressure is managed effectively underneath the triple point. The vapor formed is drawn out frequently to prevent a pressure upsurge that would stop sublimation, which accomplishes by chilling the condenser below the model temperature (making a temperature slope).
- The vapor is dragged to the chiller surface and imprisoned in the form of ice. Primary drying (sublimation) eradicates the bulk of the icy free water by heating in a series of thermal ramps to room temperature beneath reduced pressure.
- Additionally, elevating the temperature at the termination of the primary drying process to above room temperature eradicates the residual humidity, which adsorbs onto the model (secondary drying) [23]— a representation of a distinctive freeze-dryer as given away in (Fig. 4).
A distinctive freeze-dryer comprises temperature-controlled ramps, a condenser to trap water detached from the substantial, a freezing system to supply the shelves and condenser with coolant, and a lower vacuum device for the chamber pressure. The freeze-drying stages are generally programmed via computer through suitable freeze-dryer software.

Freeze-drying of polymer gels to acquire wafers can generally undertake with the help of a laboratory-scale freeze-dryer [23,24].

3.2 Lyophilization (Freeze Drying)

The primary Lyophilization method consists of the following steps: Graphically explained in (Fig. 5).

- It is a Freeze drying process in which polymer substrate and a plasticizer, preservative and antibacterial or antifungal medicament homogenously mixed with the high-speed stirrer such as a Mechanical stirrer or Magnetic stirrer [24].
- Later this homogenous mixture or gel is poured into a mold or petri-dish previously greased with the greasing agents. Then it is frozen at approximately -0°C to -80°C (Primary drying) for overnight or a few hours as per formulation requirement [23,25].
- Then, the frozen formulation dried in a series of thermal ramps (secondary drying) in the presence of Vacuum to remove ice formed between the matrix of polymer and drug. This cycle is carried out even for few hours to days [23].

3.3.1 Calcium alginate

When calcium alginate (CA) consumed by living tissue, these compounds’ evident lack of toxicity significantly attracted alginates. Calcium alginate (CA), and alginic acid calcium salt, are derived from brown seaweed and consist of alternating β-(1–4) D-mannuronic acid (M-blocks) and α-(1–4) L-guluronic acid sequences (G-blocks). The proportionate dispersal of the blocks is contingent upon the source. The seaweed uses different conformational structures with mannuronic and guluronic acid residues [27]. The conformational study showed that the M-block residues of the di-equatorial mannuronic acid. Flexible, flat ribbon-like chain conformation show. On the other hand, in G-block, the diaxially related guluronic acid residues show rigid structures [28]. Due to its hemostatic properties, calcium alginate has applications in heavily exuding lesions like DFUs and pressure-induced leg ulcers. It interchanges calcium ions with blood-present sodium particles (wound exudate) that activate growth factors, including growth factors derived from platelets and cytokines, which play a crucial part in cell enrollment and extracellular deposition matrix [29].

3.3.2 Carrageenan (CAR)

Carrageenan is a sulfated natural polymer formed from red seaweed generally used in food
manufacturing as a thickening medium [30]. Various grades are assorted according to the number of sulfate groups present Kappa (k) CAR (one sulfate group) gives rise to a thermoreversible sol-gel in an aqueous medium, which undertakes dispersal subsequent random-coil development in the early phase. At low temperatures, galactose sequences within the CAR chains turn in a double-helix manner. The sugary taste of galactose might help cover some drug's unpleasant taste, thus evading flavoring and sweetener agents [31]. Numerous spots for hydrogen bonding impart bioadhesive features. However, this could improve by ionic bond development between the negatively charged sulfate group, and the mucin existing in the oral mucosa is a positive charge [32]. Poloxamer 407 is a block copolymer encompassing Polyethylene glycol (PEG) and propylene oxide [33]. It is a non-ionic surfactant with the capability to escalate drugs' solubility (e.g. ibuprofen) with high log P [34].

![Fig. 3. Represents phase diagram of water](image1)

![Fig. 4. Graphical representation of freeze drier components](image2)
3.3.3 Thiolated chitosan

Synthetic polymers, such as thiolated Chitosan that is stated to be up to 10 times additionally bioadhesive than Chitosan but still biodegradable, can be formulated with wafers [35].

Among the numerous bioadhesive polymers employed, Chitosan (CS) is one of the utmost generally reported. Because of its well-established bioadhesive properties [36]. Due to its biocompatibility and biodegradation properties. CS has been used principally to enhanced mucoadhesion, infiltration enhancement, and drug delivery via mucosal routes such as GI, buccal, and ocular mucosa [37]. The bioadhesive property of CS is reporting to be enhanced by the thiolation of the parental CS mediety ensuing in the formation of numerous thiolated CS derivatives [38]. The thioalkylamidine substitute incorporates without the establishment of N-substituted non-thiol substrates to obtain thiolated Chitosan. By means of the immobilization of thiol groups, mucoadhesion was enormously improving due to disulfide bonds with mucus glycoproteins [39].

3.4 Role of Backing Layer and Plasticizer in Wafer Formulation

The key role of a backing layer in Topical Drug delivery is to protect the patch from environmental stress, keep the patch adhere to the required site, and protect the photosensitive drugs by reflecting the light. It also needs to be flexible, comfortable, and empathize with the adhesive and excellent printability. Some of the backing ingredients are Vinyl, Polyethylene, Polyester films, Aluminum and Polyolefin films. The most common release liners are Polyacrylate, Polyethylene, Polyvinylchloride, Silicon, Teflon, and Paper fabric will be using as a backing layer [40,41].

Besides, plasticizers such as Dibutyl phthalate, triethyl citrate, Polyethylene glycol, propylene glycol, and glycerin add plasticity to the wafer formulation [40].

4. WAFER EVALUATION PARAMETERS

4.1 Characterization Studies

a. X-Ray Diffraction (XRD): The need for this study is to evaluate the physical nature (Crystalline or Amorphous) of pure drug, polymer, blank wafer formulation, and drug-loaded wafer formulation [3].

b. HPLC analysis: This study analyzes the data and separates the analyte to know the components’ purity and mobile phase selected based on the drug’s solubility [42].

c. FTIR studies: In this study, the compatibility, i.e., any chemical interaction between the polymer and drug, can be
detected by Fourier Transform Infrared Spectroscopy (FTIR) instrument [3,43,44].

4.2 Post Formulation Studies

a. **SEM (Scanning Electron Microscopy):** In this evaluation parameter, the Surface morphology of wafer formulation will study by having a magnification look at 200x at a low fast-tracking electrical energy of 1.0kV [3,45].

b. **Texture analysis:** In this study, the mechanical hardness and in-vitro adhesion of wafer formulation will determine using a texture analyzer operated by Texture Exponent 32 software [5,46].

c. **Fluid(exudate) handling properties:** The Fluid exudate handling properties of the wafer formulation can be determined by pouring 5 g of SWF in a petri dish placed on the weighing machine and then immersing the wafer formulation in 5 g SWF for 3 hours to know the exudate handling property. At the same time, it will also be used to measured to know the water-absorbing capacity, water holding capacity, and rate of water uptake by the wafer formulation just by pouring a more weighed quantity of SWF until it forms into liquid [3,47].

d. **Folding Endurance:** The wafer formulation should be folded repeatedly in one place until breaks show the elasticity of the wafer formulation. It should withstand a minimum of 300 folds manually [48].

e. **DSC studies:** Differential Scanning Calorimetry (DSC) is an instrument used to measure enthalpy changes due to change in the material's physical and chemical nature due to exposure to a different temperature [3,4,48].

f. **In-vitro studies:** In this study, the drug release profile of drug-loaded wafer formulation will be studying using culture plates containing human primary epidermal keratinocytes, Franz diffusion cell, and culture plates containing Gram-Positive and Gram-Negative bacterial growth [46,47,49].

g. **In-vivo studies:** This study will be performing on the animal by following the guidelines as per the Ethics committee with the permission of IAEC (Institutional Animal Ethical Committee). In a study conducted by et al. Mahalaxami Rathnanand, Diabetes should be induced in the rats of either sex with Streptozotocin, and excision of 1x1 cm² should be made on the rats after anesthetized with the help of Ketamine HCL + Xylazine. Afterward, wafer formulation is placed with adhesive paper tape, and shrinking of the wound to be measured with a scale and observed for 14 days [29,46,47].

h. **Gamma-irradiation:** It is a Gamma radiation emitting device that will help sterilize the wafer formulation and know any rheological changes in wafer formulation due to gamma rays [50,51].

i. **Stability studies:** As per ICH guidelines, a short-term stability study will be carried at 40°C ± 2°C at 75±5 RH for six months [52–54].

5. CONCLUSION

This review explains the development and stages of diabetic foot ulcer infections, some major bacterial species involved in them, and risks of diabetic foot ulcer infections, along with an example of some marketed medications used to control such conditions. Along with diabetic foot ulcer infections, this review hypothesizes the wafer formulation's safe outcomes, suggests a common method to prepare it and describes the different stages of the process carried in a lyophilizer. Furthermore, this review suggests the importance of wafer formulation and selection of polymers, plasticizers, backing layers. It also throws some lights on various evaluation parameters before developing the wafer formulation and tests after preparing the formulation.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.
ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENTS

The authors duly acknowledged the president Dr. Devanshu J Patel of Parul University and the entire team of CR4D of Parul University for providing facilities and showed keen interest in our work, encouraged to bring the best out of us. I have expressed my sincere thanks to the Pharmacetics Department at Parul Institute of Pharmacy and Research, Parul University, for providing continuous support and facility throughout my work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ramirez-Acuña JM, Cardenas-Cadena SA, Marquez-Salas PA, Garza-Veloz J, Perez-Favila A, Cid-Baez MA, Flores-Morales V, Martinez-Fierro ML. Diabetic foot ulcers: Current advances in antimicrobial therapies and emerging treatments. Antibiotics. 2019;8:193. DOI:https://doi.org/10.3390/antibiotics8040193

2. Boulton AJM. The diabetic foot. Elsevier Ltd; 2019. DOI:https://doi.org/10.1016/j.mpmed.2018.11.001

3. Ahmed A, Getti G, Boateng J. Ciprofloxacin-loaded calcium alginate wafers prepared by freeze-drying technique for potential healing of chronic diabetic foot ulcers. Drug Deliv. Transl. Res. 2018;8:1751–1768. DOI:https://doi.org/10.1007/s13346-017-0445-9

4. Boateng JS, Matthews KH, Stevens HNE, Eccleston GM. Wound healing dressings and drug delivery systems: A review. J. Pharm. Sci. 2008;97:2892–2923. DOI: https://doi.org/10.1002/jps.21210

5. Pawar HV, Boateng JS, Ayensu I, Tetteh J. Multifunctional medicated lyophilized wafer dressing for effective chronic wound healing. J. Pharm. Sci. 2014;103:1720–1733. DOI: https://doi.org/10.1002/jps.23968

6. Garraud O, Hozzein WN, Badr G. Wound healing: Time to look for intelligent, "natural" immunological approaches? BMC Immunol. 2017;18. DOI:https://doi.org/10.1186/s12865-017-0207-y

7. Zontangos G, Anderson A. OpenAIR @ RGU The Open Access Institutional Repository at Robert Gordon University, Qual. Mark. Res. Int. J. 2004;7:228–236. DOI:https://doi.org/10.1177/0266242610391936

8. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N. Engl. J. Med. 2017;376:2367–2375. DOI:https://doi.org/10.1056/nejmra1615439

9. PDF Bandyk. The diabetic foot: Pathophysiology, evaluation and treatment. Semin. Vasc. Surg. 2018;31:43–48. DOI:https://doi.org/10.1053/j.semvascsurg.2019.02.001

10. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vonore JV. Diabetic foot disorders: A Clinical practice guideline (2006 Revision). J. Foot Ankle Surg. 2006;45:1–66. DOI:https://doi.org/10.1016/S1067-2516(07)60001-5

11. Noor S, Zubair M, Ahmad J. Diabetic foot ulcer - A review on pathophysiology, classification and microbial etiology. Diabetes Metab. Syndr. Clin. Res. Rev. 2015;9:192–199. DOI:https://doi.org/10.1016/j.dsx.2015.04.007

12. Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41:645–652. DOI: https://doi.org/10.2337/dc17-1836

13. Chellan G, Shivaprakash S, Ramaiyar SK, Varma AK, Varma N, Sukumaran MT, Vasukutty JR, Bal A, Kumar H. Spectrum and prevalence of fungi infecting deep tissues of lower-limb wounds in patients with type 2 diabetes. J. Clin. Microbiol. 2010;48:2097–2102. DOI:https://doi.org/10.1128/JCM.02035-09

14. Taj-Aldeen SJ, Talal TK, Menzies RA, Stevens D, Herron P. Fungal infections of
the diabetic foot. Foot Ulcers Causes, Diagnosis, Treat. 2009;267–284.
15. Barchielli VT, Dolfini M, Farina E, Leoni P, Targa B, Vinacca G. Clinical pharmacokinetics of Lercanidipine. J. Cardiovasc. Pharmacol. 1997;29. Available:https://journals.lww.com/cardiovascularcharmph/Fulltext/1997/29002/Clinical_Pharmacokinetics_of_Lercanidipine.2.aspx
16. Clayton W, Easy TA. A review of the pathophysiology, classification and treatment of foot ulcers in diabetic patients. Clin. Diabetes. 2009;27:52–58. DOI: https://doi.org/10.1002/dmrr.833
17. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157–162. DOI:https://doi.org/10.2337/diacare.22.1.157
18. Boulton AJM. The diabetic foot: Grand overview, epidemiology and pathogenesis, diabetes. Metab. Res. Rev. 2008;24:S3–S6. DOI: https://doi.org/10.1002/dmrr.833
19. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N. Engl. J. Med. 2017;376:2367–2375. DOI:https://doi.org/10.1056/NEJMra16154
20. Rezvanian M, Tan C-K, Ng S-F. Simvastatin-loaded lyophilized wafers as a potential dressing for chronic wounds. Drug Dev. Ind. Pharm. 2016;42:2055–2062. DOI:https://doi.org/10.1080/03639045.2016.6119540
21. Auffret D, Anthony M, Eccleston, Gillian J. Humphrey, Michael H. Matthews, Kerr E. Stevens, Howard Norman. Wafer for wounds. WO 03/037395A1; 2003. Available:https://patentscope.wipo.int/search/en/detail.jsf?docid=WO2003037395
22. Khan I, Elhissi A, Shah M, Alhnan MA, Ahmed W. Liposome-based carrier systems and devices used for pulmonary drug delivery. In Biomater. Med. Tribol. Res. Dev., Elsevier. 2013;395–443. DOI:https://doi.org/10.1533/978085709220 5.395
23. Ng S. Freeze-dried wafers for wound healing. In Ther. Dressings Wound Heal. Appl., Wiley, 2020;137–155. DOI:https://doi.org/10.1002/978111943331 6.ch7
24. Kasper JC, Friess W. The freezing step in Lyophilization: Physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm. 2011;78:248–263. DOI:https://doi.org/10.1016/j.ejpb.2011.03.010
25. Qinghai Zhao JB, Xia Luo. Lyophilization process. WO 2014/113358 A1; 2014. Available:https://patents.google.com/patent /WO2014113358A1/en?oq=WO+2014%2F113358+Al
26. Shingade GM. Review on recent trend on Transdermal drug delivery system. J. Drug Deliv. Ther. 2012;2. DOI: https://doi.org/10.22270/jddt.v2i1.74
27. Malafaya PB, Silva GA, Reis RL. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 2007;59:207–233. DOI:https://doi.org/10.1016/j.addr.2007.03.012
28. Daemi H, Barikani M. Synthesis and characterization of calcium alginate nanoparticles, sodium homopolymannuronate salt and its calcium nanoparticles. Sci. Iran. 2012;19:2023–2028. DOI:https://doi.org/10.1016/j.jiaddr.2007.03.012
29. Ahmed A, Boateng J. Calcium alginate-based antimicrobial film dressings for potential healing of infected foot ulcers. Ther. Deliv. 2018;9:185–204. DOI: https://doi.org/10.1016/j.tde-2017-0104
30. Yuguchi Y, Urakawa H, Kajiwara K. Structural characteristics of carrageenan gels: Various counter ions. Food Hydrocoll. 2003;17:481–485. DOI:https://doi.org/10.1016/S0268-05X(03)00021-3
31. Tari O, Kara S, Pekcan Ö. Critical exponents of Kappa Carrageenan in the Coil-Helix and Helix-Coil hysteresis loops. J. Macromol. Sci. Part B. 2009;48:812–822. DOI:https://doi.org/10.1080/002223409029 56129
32. Thommes M, Kleinebudde P. Use of κ-carrageenan as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type. Eur. J. Pharm. Biopharm. 2006;63:68–75.
33. Shen YR, Kuo MI. Effects of different carrageenan types on the rheological and water-holding properties of tofu. LWT - Food Sci. Technol. 2017;78:122–128. DOI:https://doi.org/10.1016/j.lwt.2016.12.038

34. Mangione M, Giacomazza D, Bulone D, Martorana V, San Biagio P. Thermoreversible gelation of κ-Carrageenan: The relation between conformational transition and aggregation. Biophys. Chem. 2003;104:95–105. DOI:https://doi.org/10.1016/S0301-4622(02)00341-1

35. Costa JSR, de Oliveira Cruvinel K, Oliveira-Nascimento L. A mini-review on drug delivery through-wafer technology: Formulation and manufacturing of buccal and oral lyophilizes. J. Adv. Res. 2019;20:33–41. DOI:https://doi.org/10.1016/j.jare.2019.04.010

36. Boateng JS, Ayensu I. Preparation and characterization of laminated thiolated chitosan-based freeze-dried wafers for potential buccal delivery of macromolecules. Drug Dev. Ind. Pharm. 2014;40:611–618. DOI:https://doi.org/10.1016/j.ijpb.2011.11.004

37. Ayensu I, Mitchell JC, Boateng JS. Development and physicomechanical characterization of lyophilized chitosan wafers as potential protein drug delivery systems via the buccal mucosa. Colloids Surfaces B Biointerfaces. 2012;91:258–265. DOI:https://doi.org/10.1016/j.colsurfb.2011.06.005

38. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials. 2007;28:2233–2243. DOI:https://doi.org/10.1016/j.biomaterials.2007.01.005

39. Kafedjiiski K, Krauland AH, Hoffer MH, Bernkop-Schnürch A. Synthesis and in vitro evaluation of a novel thiolated chitosan. Biomaterials. 2005;26:819–826. DOI:https://doi.org/10.1016/j.biomaterials.2004.03.011

40. Rastogi V, Yadav P. Transdermal drug delivery system: An overview. Asian J. Pharm. 2012;6:161. DOI:https://doi.org/10.4103/0973-8398.104828

41. Verma G. Transdermal drug delivery system, advance development and evaluation: A review. Int. J. Pharm. Sci. Res. 2017;8:385–400. DOI:https://doi.org/10.13040/IJPSR.0975-8232.8(2).385-00

42. Sallam NM, Sanad RAB, Ahmed MM, Khafagy ES, Ghobrial M, Gad S. Impact of the mucoadhesive lyophilized wafer loaded with novel carvedilol nano-spanplastics on biochemical markers in the heart of spontaneously hypertensive rat models. Drug Deliv. Transl. Res.; 2020. DOI:https://doi.org/10.1007/s13346-020-00814-4

43. Yassin GE, Dawoud MHS, Wasfi R, Maher A, Fayez AM. Comparative lyophilized platelet-rich plasma wafer and powder for wound-healing enhancement: Formulation, in vitro in vivo studies. Drug Dev. Ind. Pharm. 2019;45:1379–1387. DOI:https://doi.org/10.1080/03639045.2019.1620269

44. Haag M, Brünig M, Molt K. Quantitative analysis of diphenhydramine hydrochloride in pharmaceutical wafers using near-infrared and Raman spectroscopy. Anal. Bioanalog. Chem. 2009;395:1777–1785. DOI:https://doi.org/10.1007/s00216-009-3130-0

45. Asai J, Takenaka H, Hirakawa S, Sakabe JI, Hagura A, Kishimoto S, Maruyama K, Kajiya K, Kinoshita S, Tokura Y, Katao N. Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am. J. Pathol. 2012;181:2217–2224. DOI:https://doi.org/10.1016/j.ajpath.2012.08.023

46. Atia NM, Hazzah HA, Gaafar PME, Abdallah OY, Diosmin nanocrystal–loaded wafers for treatment of diabetic ulcer: In vitro and in vivo evaluation. J. Pharm. Sci. 2019;108:1857–1871. DOI:https://doi.org/10.1016/j.xphs.2018.12.019

47. Afjoul H, Shamloo A, Kamali A. Freeze-gelled alginate/gelatin scaffolds for wound healing applications: An in vitro, in vivo study. Mater. Sci. Eng. C. 2020;113.
48. Tabassum A, Furtado SC, Bharath S. Development of antimicrobial colloidal silver incorporated lyophilized biopolymer wafers for wound care. Wound Med. 2018;21:1–7. DOI: https://doi.org/10.1016/j.wndm.2018.04.001

49. Boateng JS, Matthews KH, Auffret AD, Humphrey MJ, Stevens HN, Eccleston GM. In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as a model soluble drug. Int. J. Pharm. 2009;378:66–72. DOI: https://doi.org/10.1016/j.ijpharm.2009.05.038

50. Simões D, Miguel SP, Ribeiro MP, Coutinho P, Mendonça AG, Correia IJ. Recent advances on antimicrobial wound dressing: A review. Eur. J. Pharm. Biopharm. 2018;127:130–141. DOI: https://doi.org/10.1016/j.ejpb.2018.02.022

51. Matthews KH, Stevens HNE, Auffret AD, Humphrey MJ, Eccleston GM. Gamma-irradiation of lyophilized wound healing wafers. Int. J. Pharm. 2006;313:78–86. DOI: https://doi.org/10.1016/j.ijpharm.2006.01.023

52. Kasper JC, Friess W. The freezing step in Lyophilization: Physico-chemical fundamentals, freezing methods, and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm. 2011;78:248–263. DOI: https://doi.org/10.1016/j.ejpb.2011.03.010

53. Xia YN, Li XH, Xu JH, Chen LQ, Ahmed AMQ, Cao D, Du HH, Deng Y, Cao QR. Optimization and characterization of novel sustained release super micro-pellet based dry suspensions that load dexibuprofen. J. Drug Deliv. Sci. Technol. 2020;55:101420. DOI: https://doi.org/10.1016/j.jddst.2019.10.042

54. NR, Khatri S, Rathnand M. Formulation and evaluation of wound healing activity of linezolid topical preparations on diabetic rats. Int. J. Appl. Pharm. 2016;8:30–36. DOI: https://doi.org/10.22159/ijap.2016v8i3.12889

© 2021 Jani et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.